

## Assoc. Prof. NEYRAN KERTMEN

### Personal Information

Office Phone: [+90 312 305 2927](tel:+903123052927)

Office Phone: [+90 312 305 2929](tel:+903123052929)

Fax Phone: [+90 312 305 2929](tel:+903123052929)

Email: [neyran.kertmen@hacettepe.edu.tr](mailto:neyran.kertmen@hacettepe.edu.tr)

Web: <https://avesis.hacettepe.edu.tr/neyran.kertmen>

### International Researcher IDs

ORCID: 0000-0001-7654-5822

Yoksis Researcher ID: 197270

### Education Information

Post Doctorate of Medicine, Hacettepe University, Tıp Fakültesi , Medikal Onkoloji , Turkey 2010 - 2013

Expertise In Medicine, S.B.Dışkapı Yıldırım Beyazıt.E.A.H, İç Hastalıkları , İç Hastalıkları , Turkey 2004 - 2009

Postgraduate, Gazi University, Tıp Fakültesi , Tıp Fakültesi , Turkey 1998 - 2004

### Foreign Languages

English, B2 Upper Intermediate

### Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

### Academic Titles / Tasks

Assistant Professor, Hacettepe University, Kanser Enstitüsü, Klinik Onkoloji Anabilim Dalı, 2016 - Continues

Expert, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2013 - 2016

### Courses

KLİNİK EĞİTİM (CLINICAL TUTORIAL), Postgraduate, 2017 - 2018, 2016 - 2017

YATAK BAŞI DOKTOR EĞİTİMİ (BEDSIDE), Postgraduate, 2017 - 2018, 2016 - 2017

KONSULTAN VİZİTİ (ROUNDS WITH THE CONSULTANT), Postgraduate, 2017 - 2018, 2016 - 2017

PRÖPEDÖTİK, Postgraduate, 2017 - 2018, 2016 - 2017

### Published journal articles indexed by SCI, SSCI, and AHCI

1. **Hypo-fractionated Stereotactic Re-Irradiation Outcomes For Recurrent Glioblastoma**  
Yılmaz M. T., KAHVECİOĞLU A., Mohammadipur S., Zorlu F., Oge K., KERTMEN N., YAZICI G.

RADIOTHERAPY AND ONCOLOGY, 2024 (SCI-Expanded)

- II. **Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years' experience of a single center**  
Yilmaz M. T., KAHVECİOĞLU A., YAZICI G., Mohammadipour S., KERTMEN N., Cifci G. C., ZORLU A. F.  
Journal of Neuro-Oncology, vol.167, no.2, pp.295-303, 2024 (SCI-Expanded)
- III. **Acute heart failure following pazopanib treatment: a literature review featuring two case reports**  
KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.  
Anti-Cancer Drugs, vol.35, no.3, pp.302-304, 2024 (SCI-Expanded)
- IV. **Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia**  
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., GÜNER G., GÜVEN D. C., ARIK Z., KERTMEN N., et al.  
Current Oncology, vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded)
- V. **SMART syndrome: a case report**  
Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., Oguz K. K., DİZDAR Ö.  
ACTA NEUROLOGICA BELGICA, vol.123, no.3, pp.1137-1140, 2023 (SCI-Expanded)
- VI. **KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer**  
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., ŞAHİN Y., Ileri S., Karaca E., KERTMEN N., et al.  
Biomarkers in Medicine, vol.17, no.7, pp.379-389, 2023 (SCI-Expanded)
- VII. **Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment**  
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., AKSOY S.  
Expert Review of Anticancer Therapy, vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded)
- VIII. **Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards**  
GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., ARIK Z., DİZDAR Ö., ÜNAL S., METAN G., et al.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.8, pp.1807-1811, 2022 (SCI-Expanded)
- IX. **Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer**  
YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.  
JOURNAL OF CLINICAL MEDICINE, vol.11, no.9, 2022 (SCI-Expanded)
- X. **HER2-low breast cancer could be associated with an increased risk of brain metastasis**  
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., KERTMEN N., DİZDAR Ö., ÜNER A., AKSOY S.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.27, no.2, pp.332-339, 2022 (SCI-Expanded)
- XI. **The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study**  
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., KERTMEN N., DİZDAR Ö., AKSOY S.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded)
- XII. **Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience**  
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., GÜVEN D. C., Olgun P., KERTMEN N., DİZDAR Ö., et al.  
FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded)
- XIII. **The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme**  
GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.  
FUTURE ONCOLOGY, vol.17, pp.4405-4413, 2021 (SCI-Expanded)
- XIV. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)

- XV. **Sarcopenia and anthracycline cardiotoxicity in patients with cancer**  
BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., BARIŞTA İ., GÜNER G., GÜVEN D. C., KERTMEN N., et al.  
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- XVI. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**  
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.  
SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)
- XVII. **Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience**  
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., TABAN H., GÜVEN D. C., KERTMEN N., Oksuzoglu B., et al.  
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XVIII. **Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma**  
BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., ERMAN M.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.5, pp.1230-1233, 2020 (SCI-Expanded)
- XIX. **Depression and anxiety in oncology nurses.**  
Keskin O., Oktay E., Turan M., Kertmen N., Tanriverdi O., Imamoglu G. I., Yuce D., Ozturk B., Ata O.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XX. **Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers**  
Karakas Y., KERTMEN N., LAÇIN Ş., Aslan A., DEMİR M., ATEŞ Ö., AKSOY S., Altundag K.  
JOURNAL OF BUON, vol.22, no.3, pp.623-627, 2017 (SCI-Expanded)
- XXI. **Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience**  
Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., Unlu O., ATEŞ Ö., DIKER O., AKIN S., et al.  
JOURNAL OF BUON, vol.21, no.4, pp.826-831, 2016 (SCI-Expanded)
- XXII. **Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors**  
ATEŞ Ö., SOYLU C., BABACAN T., Sarici F., KERTMEN N., Allen D., SEVER A. R., Altundag K.  
SPRINGERPLUS, vol.5, 2016 (SCI-Expanded)
- XXIII. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**  
ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., Karakas Y., KILIÇKAP S., Ozisik Y., SEVER A. R., et al.  
JOURNAL OF BUON, vol.21, no.2, pp.375-381, 2016 (SCI-Expanded)
- XXIV. **Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75**  
Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., ÖZDEMİR E., BARIŞTA İ., Turker A., Kars A.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.2, pp.89-95, 2016 (SCI-Expanded)
- XXV. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer**  
BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., Sarici F., KERTMEN N., Esin E., AKIN S., et al.  
TUMORI J, vol.101, no.4, pp.418-423, 2015 (SCI-Expanded)
- XXVI. **The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality**

- Solak M., Turkoz F. P., Keskin O., AKSOY S., BABACAN T., Sarici F., KERTMEN N., SEVER A. R., Altundag K.  
JOURNAL OF BUON, vol.20, no.3, pp.737-745, 2015 (SCI-Expanded)
- XXVII. **Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis**  
BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., AKIN S., ATEŞ Ö., Karakas Y., Aslan A., et al.  
JOURNAL OF BUON, vol.20, no.2, pp.479-486, 2015 (SCI-Expanded)
- XXVIII. **Comparison of three different induction regimens for nasopharyngeal cancer**  
KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., Sarici F., AKIN S., Altundag K., Gullu H. I.  
Asian Pacific Journal of Cancer Prevention, vol.16, no.1, pp.59-63, 2015 (SCI-Expanded)
- XXIX. **Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab**  
ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.  
JOURNAL OF BUON, vol.20, no.1, pp.349, 2015 (SCI-Expanded)
- XXX. **A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature**  
Keskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., Gullu I.  
JOURNAL OF BUON, vol.20, no.1, pp.348, 2015 (SCI-Expanded)
- XXXI. **Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats**  
KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t., furkan s., arik z., akin S.  
Anticancer Research, 2015 (SCI-Expanded)
- XXXII. **The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients**  
BABACAN T., Balakan O., Kuzan T. Y., Sarici F., Koca E., KERTMEN N., Petekkaya I., Altundag K.  
JOURNAL OF BUON, vol.20, no.1, pp.50-56, 2015 (SCI-Expanded)
- XXXIII. **Molecular subtypes in patients with inflammatory breast cancer; A single center experience**  
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., ARIK Z., Aslan A., ATEŞ Ö., AKSOY S., et al.  
JOURNAL OF BUON, vol.20, no.1, pp.35-39, 2015 (SCI-Expanded)
- XXXIV. **A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer**  
Buyukhatipoglu H., BABACAN T., KERTMEN N., Balakan O., Suner A., ATEŞ Ö., Sarici F., Aslan A., DIKER O., Tasdemir V., et al.  
JOURNAL OF BUON, vol.20, no.1, pp.22-27, 2015 (SCI-Expanded)
- XXXV. **Association between common risk factors and molecular subtypes in breast cancer patients**  
Turkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., ARIK Z., BABACAN T., Ozisik Y., Altundag K.  
BREAST, vol.22, no.3, pp.344-350, 2013 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Low-grade glial tumors: The experience of an oncology hospital in Türkiye**  
CEYLAN S., KERTMEN N., YAZICI G., KARS A.  
Acta Medica, vol.54, no.2, pp.151-156, 2023 (Peer-Reviewed Journal)
- II. **Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?**  
Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., MUT AŞKUN M., ERMAN M., Soylemezoglu F., Zorlu F., et al.  
CUREUS, vol.13, no.6, 2021 (ESCI)
- III. **which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats**

## Refereed Congress / Symposium Publications in Proceedings

- I. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**  
Güven D. C., AKTEPE O. H., Berk Z., Güner G., Taban H., AKTAŞ B. Y., Duran Z. C., AKIN Ş., ARIK Z., KERTMEN N., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- II. **Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**  
AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Güven D. C., AKTEPE O. H., Güner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- III. **Depression and anxiety in oncology nurses.**  
KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU İNANÇ G., YÜCE D., ÖZTÜRK B., ATA Ö.  
2018 ASCO Annual Meeting, United States Of America, 5 - 08 June 2018, pp.18552
- IV. **Onkoloji Hemşirelerinde depresyon ve anksiyete**  
KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU G. İ., YÜCE D.  
22.ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- V. **TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ**  
KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., SARICI F., ATEŞ Ö., ALTUNDAĞ M. K.  
22. UKK, Turkey, 19 - 23 April 2017
- VI. **Intravenous ferric carboxymaltose treatment in cancer patients**  
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- VII. **Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma**  
ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., TÜRKER F. A., KARS S. A.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- VIII. **Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoğlu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever**  
ALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOĞLU H., BALAKAN O., SARICI F. S., KERTMEN N., ESİN E., et al.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- IX. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**  
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., KARAKAS Y., KILIÇKAP S., AKSOY S., ÖZİŞİK Y. Y., et al.  
ASCO Annual Meeting, 29 May - 02 June 2015
- X. **Neuroendocrine breast cancer A single center experience**  
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., DİZDAR Ö., AKSOY S., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XI. **Tumor locations significantly affect disease free survival and overall survival**  
BUYUKHATİPOĞLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., AKSOY S., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015

- XII. **Signet ring cell carcinoma of breast: Single center experience.**  
 AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.  
 Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIII. **Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.**  
 Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., Unlu O., Ates O., Sarici S. F., Akin S., et al.  
 Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIV. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.**  
 Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., Sarici F. S., Kertmen N., Esin E., et al.  
 Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XV. **Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.**  
 Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., Sarici S. F., Akin S., Altundag K., Gullu I. H.  
 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVI. **Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats**  
 Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarici S. F., Sendur M. A. N., Arik Z., et al.  
 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVII. **Clinicopathologic characteristics of pure papillary breast carcinoma**  
 Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., Aksoy S., Altundag K.  
 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XVIII. **Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.**  
 Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C., Babacan T., Sahin U., Keskin O., Kertmen N., Aksoy S., et al.  
 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XIX. **The impact of adjuvant delayed radiotherapy (RT) on survival in patients with resected periampullary adenocarcinomas.**  
 Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.  
 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

## Metrics

Publication: 58

Citation (WoS): 164

Citation (Scopus): 115

H-Index (WoS): 6

H-Index (Scopus): 7

## **Non Academic Experience**

PROF.DR.CELAL ERTUĞ ETİMESGUT DEVLET HASTANESİ  
PROF.DR.CELAL ERTUĞ ETİMESGUT DEVLET HASTANESİ